Výsledky vyhledávání - "Aristeidis, Vaiopoulos"

Akademický článek

The Effect of 4-Month Treatment with Glycocalyx Dietary Supplement on Endothelial Glycocalyx Integrity and Vascular Function in Patients with Psoriasis

Autor: Ignatios Ikonomidis, Eleni Katsanaki, John Thymis, George Pavlidis, Kyriaki Lampadaki, Konstantinos Katogiannis, Aristeidis Vaiopoulos, Vicky Lazarou, Gavriella Kostelli, Eleni Michalopoulou, Sotirios Pililis, Dimitrios Vlachomitros, Konstantinos Theodoropoulos, Hans Vink, Robert Long, Evangelia Papadavid, Vaia Lambadiari

Publikováno v: Nutrients, Vol 16, Iss 15, p 2572 (2024)

Psoriasis predisposes to cardiovascular dysfunction. We investigated whether glycocalyx dietary supplement (GDS), which contains glycosaminoglycans and fucoidan, improves endothelial glycocalyx and arterial stiffness in psoriatic patients. Fifty part

Externí odkaz: https://doaj.org/article/5f19ade2e25449bd8a3f7345b2297801

Zobrazit plný text záznamu

Akademický článek

Case Report: PsAPSASH syndrome: an alternative phenotype of syndromic hidradenitis suppurativa treated with the IL-17A inhibitor secukinumab [version 2; peer review: 2 approved]

Autor: Georgios Nikolakis, Katja Kreibich, Aristeidis Vaiopoulos, Katarzyna Kaleta, Joud Talas, Markus Becker, Christos C. Zouboulis

Publikováno v: F1000Research, Vol 10 (2021)

Syndromic hidradenitis suppurativa (HS) is a form of symptom constellations, which differs from the familial and genetic form and comprises predominantly osteoarticular manifestations. Many forms include pyoderma gangrenosum and acne (PASH), pyogenic

Externí odkaz: https://doaj.org/article/d04a23420f5f4ba4b917411dc251d51b

Zobrazit plný text záznamu

[Enlarged mediastinal lymph nodes of a patient with malignant melanoma stage IV under pembrolizumab treatment]

Autor: Georgios, Nikolakis, Martina, Brunner, Heike, Boye, Nicole, Arndt, Andreas, Altenburg, Aristeidis, Vaiopoulos, Christos C, Zouboulis

Publikováno v: Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete. 70(6)

A 40-year-old patient with malignant melanoma pT4bN0M1a stage IV (AJCC classification 2017) was treated with the PD-1/PD-L1 antibody pembrolizumab. Three months after treatment initiation the patient developed enlarged mediastinal lymph nodes despite

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::593e5d09f987277e15eb17eef2438a8b
https://pubmed.ncbi.nlm.nih.gov/30887079

Zobrazit plný text záznamu